Chikungunya Vaccine Safety and Immune Response Study
Part of Infections clinical trials.
This study tests a new vaccine to protect against chikungunya virus, a disease spread by mosquitoes that causes fever and joint pain. The study measures how well your immune system responds to the vaccine and tracks any side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 12 and 65 years old and in good overall health
- Agree to keep a diary of any symptoms and complete all study visits
- If you can have children, agree to use effective birth control for at least 3 months after your last vaccine dose
- Agree to let researchers store a blood sample for chikungunya research
- Not have had certain conditions like rheumatoid arthritis, diabetes, neurological diseases, or cancer
- Not be pregnant, breastfeeding, or recently vaccinated (within 30 days)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a vaccine for chikungunya virus in children aged 1 to 12. It aims to see if the vaccine is safe and helps the body build protection against the virus.
This study tests a new vaccine to see if it's safe and helps protect against chikungunya virus (a mosquito-borne illness causing fever and joint pain). It's for healthy adults ages 18 to 60 who haven't recently traveled to areas with similar viruses or received certain other vaccines.
This trial tests an experimental chikungunya vaccine (made from a virus-like particle) to see if it prevents the disease. It is for healthy teens and adults who have not had chikungunya before.
This trial tests whether giving two vaccines (one for dengue, one for chikungunya) at the same time is as safe and effective as giving them separately. It may be a good option if you haven't been exposed to these viruses and are generally healthy.
This study looks at how well the VLA1553 vaccine prevents chikungunya disease in parts of Brazil where the vaccine is being offered as part of a pilot program. If you live in one of those areas and have had symptoms that might be chikungunya, this study will use your health records and blood tests to check how effective the vaccine is.
This study follows pregnant women who received the VLA1553 vaccine (for chikungunya) to see how it affects them and their babies. It compares them to pregnant women who received a different vaccine approved during pregnancy.
Hear when a new Active Immunisation for Chikungunya Virus Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.